IFNA1 and rheumatoid arthritis: Predictive biomarkers in peripheral blood samples can identify patients with intracranial aneurysms37, be used to stratify patients according to disease progression before and after the onset of type 1 diabetes38–41, and classify systemic lupus erythematosus and rheumatoid arthritis by prediction of their responsiveness to anti-IFN therapy42,43.